Spotify Apple Youtube

Category: Hepatology

All Podcast Categories
S4-19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?

S4-19.6 – From the Vault: REGENERATE Redux: Clearing The Finish Line?

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.

May 7, 2023
S4-19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

S4-19.5 – Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this final conversation, each describes the most important thing they would like ICER to learn before another NASH drug analysis.

May 7, 2023
S4-19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-19.4 – Patient Advocates Describe the Reasoning Behind Their Testimonies

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.

May 7, 2023
S4-19.3 - The Role of Biopsy in Prescribing NASH Therapeutics

S4-19.3 – The Role of Biopsy in Prescribing NASH Therapeutics

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group discusses the role of biopsy, drug trial endpoints and more.

May 6, 2023
S4-19.2 - Patient Advocates React to the Word “Empathy”

S4-19.2 – Patient Advocates React to the Word “Empathy”

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

May 6, 2023
S4-19.1 - How Did the Patient Advocates Come to Offer Testimonies?

S4-19.1 – How Did the Patient Advocates Come to Offer Testimonies?

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This opening conversation reveals how each guest became involved in the process and offers a preview of their reactions to the experience.

May 6, 2023
S2-4 - What Can You Do Today to Prevent and Treat Fatty Liver Disease?

S2-4 – What Can You Do Today to Prevent and Treat Fatty Liver Disease?

Ken Cusi and Roger Green are joined by Diana Barb and Jay Shubrook in a discussion around effective therapies and strategies for fighting fatty liver disease that are available now. The group discusses frontline screening, medications, bariatric surgery, lifestyle management, practical insights and much more.

May 5, 2023
S4-19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-19 – Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session regarding the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

May 4, 2023
S4-18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-18.6 – From the Vault: Clinical Care Pathway: What Can Be Done Today?

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.

April 30, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More